Travere Therapeutics (NASDAQ:TVTX) Director Sells $209,925.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Roy Baynes sold 4,500 shares of Travere Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $46.65, for a total transaction of $209,925.00. Following the transaction, the director directly owned 37,500 shares of the company’s stock, valued at approximately $1,749,375. This trade represents a 10.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Trading Down 0.1%

Shares of NASDAQ TVTX opened at $42.60 on Friday. Travere Therapeutics, Inc. has a 1 year low of $13.88 and a 1 year high of $48.61. The stock has a market cap of $3.96 billion, a P/E ratio of -185.21 and a beta of 1.13. The firm has a 50-day moving average of $32.83 and a 200 day moving average of $32.94. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The company had revenue of $127.20 million during the quarter, compared to analysts’ expectations of $136.23 million. During the same period last year, the company posted ($0.47) EPS. Travere Therapeutics’s revenue was up 55.6% on a year-over-year basis. As a group, sell-side analysts expect that Travere Therapeutics, Inc. will post -0.24 EPS for the current fiscal year.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Wall Street Analysts Forecast Growth

TVTX has been the topic of several recent research reports. Piper Sandler upgraded Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price target on the stock in a research note on Tuesday, April 14th. Citigroup upped their price target on Travere Therapeutics from $53.00 to $59.00 and gave the stock a “buy” rating in a research note on Tuesday. Wedbush upped their price target on Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a research note on Tuesday. Guggenheim upped their price target on Travere Therapeutics from $54.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Finally, Canaccord Genuity Group upped their price target on Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.83.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TVTX. Raymond James Financial Inc. bought a new position in shares of Travere Therapeutics during the 2nd quarter valued at $33,000. Fifth Third Bancorp purchased a new position in Travere Therapeutics during the first quarter valued at $35,000. First Horizon Corp purchased a new stake in Travere Therapeutics in the 3rd quarter worth $36,000. State of Wyoming bought a new stake in Travere Therapeutics during the fourth quarter valued at about $37,000. Finally, Torren Management LLC bought a new stake in Travere Therapeutics during the fourth quarter valued at about $38,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.